<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04048616</url>
  </required_header>
  <id_info>
    <org_study_id>3010</org_study_id>
    <secondary_id>1R01AG055443-01A1</secondary_id>
    <nct_id>NCT04048616</nct_id>
  </id_info>
  <brief_title>Impact of Protein and Alkali Supplementation on Skeletal Muscle in Older Adults</brief_title>
  <official_title>Impact of Protein and Alkali Supplementation on Skeletal Muscle in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Whether higher dietary protein benefits skeletal muscle health in older adults remains an
      ongoing area of investigation. This study will determine whether adding an alkaline salt
      supplement, potassium bicarbonate, to reduce the dietary acid load of a high protein diet can
      further enhance the beneficial impact of a high protein diet alone on muscle performance and
      mass in older underactive adults on baseline low protein diet.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With aging, skeletal muscle mass and performance decline leading to an increased risk of
      falls and physical disability. There is ongoing research on whether increasing dietary
      protein intake in older adults improves indices of muscle health and thus translates to a
      reduction in physical disability. A main concern is that high protein results in a large
      dietary acid load from the breakdown of protein to acidogenic byproducts, which could in turn
      promote muscle degradation particularly in older adults with age-related declines in renal
      excretion of acid. The scientific premise of this project is that the balance between the
      amount of protein in the diet (anabolic component) and the net acid load of the diet
      (catabolic component) in part determines whether the diet as a whole has a net anabolic or
      catabolic effect on muscle. Preliminary data have suggested that a daily alkaline salt
      supplement (potassium bicarbonate, KHCO3) lowered the dietary acid load and improved lower
      extremity muscle power in postmenopausal women. The investigator's central hypothesis is that
      higher protein intake plus a neutralizing alkaline salt will have additive effects on muscle
      performance and mass in older adults to either intervention alone. To test the hypothesis,
      the investigators will conduct a randomized, double-blind, placebo-controlled, 2x2 factorial
      study in which underactive men and women age 65 and older on baseline lower protein diets
      will be enrolled. Participants will assigned to one of four groups: either a whey protein
      supplement (to raise protein intake to 1.5 g/kg/d) with or without KHCO3 81 mmol/d or an
      isocaloric placebo supplement with or without KHCO3 81 mmol/d for 24 wks. The primary outcome
      is lower extremity muscle power at 24 weeks. Secondary outcomes are lower extremity muscle
      power at 12 weeks, muscle endurance at 12 and 24 weeks, physical performance at 24 weeks,
      lean mass at 24 weeks, and 24-hr urinary nitrogen excretion adjusted for nitrogen intake at
      24 weeks. Exploratory outcomes will include a measure of muscle mass - D3-creatine dilution -
      and how it correlates with lean mass. Changes in these outcomes will be compared in the 4
      groups. If successful, this research would represent a meaningful step in defining the
      circumstances under which protein has its greatest anabolic benefit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>double blind randomized placebo controlled 2x2 factorial design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lower extremity muscle power</measure>
    <time_frame>24 weeks</time_frame>
    <description>measure of muscle power using a double leg press</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lower extremity muscle power</measure>
    <time_frame>12 weeks</time_frame>
    <description>measure muscle power using double leg press</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>isokinetic leg extension strength and endurance</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>measure knee extension strength, torque and fatigability using Biodex Isokinetic Dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>handgrip strength</measure>
    <time_frame>24 weeks</time_frame>
    <description>measure strength using grip strength dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>appendicular lean body mass</measure>
    <time_frame>24 weeks</time_frame>
    <description>Dual energy X-ray absorptiometry (DXA) lean mass of arms plus legs divided by height squared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical performance battery</measure>
    <time_frame>24 weeks</time_frame>
    <description>measure performance based on Health Aging and Body Composition-Physical Performance Battery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour urinary nitrogen excretion to nitrogen intake</measure>
    <time_frame>24 weeks</time_frame>
    <description>measure based on 24 hour urine and 24 hour diet recall</description>
  </secondary_outcome>
  <other_outcome>
    <measure>D3-creatine dilution (exploratory)</measure>
    <time_frame>24 weeks</time_frame>
    <description>measure of total body muscle mass</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Age-Related Sarcopenia</condition>
  <condition>Muscle Loss</condition>
  <arm_group>
    <arm_group_label>whey protein isolate + KHCO3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.5 gm/kg/day of whey protein and 81 mmol/day of KHCO3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>whey protein isolate + microcrystalline cellulose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.5 gm/kg/day of whey protein and identical placebo microcrystalline cellulose capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maltodextrin powder + KHCO3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>isocaloric placebo maltodextrin powder and 81 mmol/day of KHCO3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maltodextrin powder + microcrystalline cellulose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>isocaloric placebo maltodextrin powder and identical placebo microcrystalline cellulose capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>whey protein isolate</intervention_name>
    <description>one 15-25 gm (based on body weight) protein packet three times a day with each meal</description>
    <arm_group_label>whey protein isolate + KHCO3</arm_group_label>
    <arm_group_label>whey protein isolate + microcrystalline cellulose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>potassium bicarbonate (KHCO3)</intervention_name>
    <description>two 13.5 mmol capsules three times a day with each meal</description>
    <arm_group_label>maltodextrin powder + KHCO3</arm_group_label>
    <arm_group_label>whey protein isolate + KHCO3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>microcrystalline cellulose</intervention_name>
    <description>identical placebo capsule</description>
    <arm_group_label>maltodextrin powder + microcrystalline cellulose</arm_group_label>
    <arm_group_label>whey protein isolate + microcrystalline cellulose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>maltodextrin powder</intervention_name>
    <description>isocaloric placebo powder</description>
    <arm_group_label>maltodextrin powder + KHCO3</arm_group_label>
    <arm_group_label>maltodextrin powder + microcrystalline cellulose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ability to sign informed consent form

          2. ambulatory community-dwelling men and women

          3. age 65 years and over

          4. habitual dietary intake of protein of ≤0.8 g/kg/d

          5. underactive

          6. estimated glomerular filtration rate ≥ 50 ml/min/1.73 m2

        Exclusion Criteria:

          1. participation in a diet or intensive exercise program during the study

          2. vegetarian (no animal protein)

          3. oral glucocorticoid use for &gt; 10 days in the last 3 months

          4. anabolic and gonadal hormones in the last 6 months

          5. Tamoxifen/raloxifene in the last 6 months

          6. regular use of alkali-producing antacids (&gt; 3 times per week)

          7. potassium-containing supplements or products

          8. non-steroidal anti-inflammatory medications &gt;3 times per week

          9. antacids containing calcium carbonate, aluminum hydroxide, magnesium hydroxide, or
             calcium acetate

         10. insulin

         11. sulfonylureas

         12. SGLT2 inhibitors

         13. a lower extremity fracture in the last year

         14. kidney stones in the past 5 years

         15. hyperkalemia

         16. elevated serum bicarbonate

         17. hypercalcemia

         18. uncontrolled diabetes mellitus defined as having fasting blood &gt;150 or hemoglobin A1c
             &gt;8%

         19. untreated thyroid or parathyroid disease

         20. significant immune disorder

         21. current unstable heart disease

         22. Crohn's disease

         23. active malignancy or cancer therapy in the last year

         24. alcohol use exceeding 2 drinks/day

         25. current peptic ulcers or esophageal stricture

         26. other condition or abnormality in screening labs, at discretion of the study physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Ceglia, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center and Tufts University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Ceglia, MD MS</last_name>
    <phone>617-556-3085</phone>
    <phone_ext>6175563085</phone_ext>
    <email>lisa.ceglia@tufts.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline Mountain</last_name>
    <phone>617-556-3072</phone>
    <phone_ext>6175563085</phone_ext>
    <email>caroline.mountain@tufts.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Ceglia</last_name>
      <phone>617-556-3085</phone>
      <phone_ext>6175563085</phone_ext>
      <email>lisa.ceglia@tufts.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Ceglia</last_name>
      <phone>6175563085</phone>
      <phone_ext>6175563085</phone_ext>
      <email>lisa.ceglia@tufts.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 5, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tufts University</investigator_affiliation>
    <investigator_full_name>Lisa Ceglia</investigator_full_name>
    <investigator_title>Asst. Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

